SCHEMBL13429182

SCHEMBL13429182

CCOc1ccc(Oc2cc(=O)[nH]c3ccccc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
L3MBTL1 Q9Y468 1/20 0.53
KDM4E B2RXH2 7/20 0.49
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47
LTA4H P09960 1/20 0.46
ALDH1A1 P00352 3/20 0.45
TSHR P16473 2/20 0.45
CTSV O60911 1/20 0.45
CTSL P07711 1/20 0.45
HSD17B10 Q99714 4/20 0.45
GRM5 P41594 1/20 0.45
GAA P10253 1/20 0.44
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ESR2 Q92731 1/20 0.43
GUSB P08236 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11380959 0.85 KDM4E (0.56) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL13429075 0.84 CYP1A2 (0.56) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL13429062 0.84 L3MBTL1 (0.60) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL2008835 0.84 HPGD (0.54) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL13429129 0.81 RHEB (0.50) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL13429212 0.81 CYP1A2 (0.47) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL13429082 0.81 CYP1A2 (0.47) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL13429066 0.81 KDM4E (0.50) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL13429113 0.81 HPGD (0.57) MEN1KMT2AL3MBTL1KDM4ECYP1A2
SCHEMBL3205961 0.81 CYP1A2 (0.47) MEN1KMT2AL3MBTL1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA MEN1 2648/4885KMT2A 2445/4885L3MBTL1 3076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.